United Therapeutics Corporation $UTHR Shares Sold by Inspire Investing LLC

Inspire Investing LLC cut its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 8.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,088 shares of the biotechnology company’s stock after selling 976 shares during the period. Inspire Investing LLC’s holdings in United Therapeutics were worth $6,575,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in shares of United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics during the 2nd quarter valued at about $277,000. Cerity Partners LLC grew its holdings in shares of United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after purchasing an additional 5,600 shares during the period. Finally, Bank of Nova Scotia grew its holdings in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at $10,540,358.40. This trade represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 633,218 shares of company stock worth $357,330,714 in the last 90 days. 8.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on UTHR. HC Wainwright lifted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Finally, Royal Bank Of Canada decreased their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Stock Performance

United Therapeutics stock opened at $544.92 on Tuesday. The company’s 50 day simple moving average is $560.52 and its 200-day simple moving average is $526.39. The company has a market capitalization of $23.13 billion, a price-to-earnings ratio of 20.12, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the company posted $6.63 earnings per share. The business’s revenue was down 1.6% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post 26.49 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.